Methods of extended use oral contraception
USRE39861E1 · kind E1 · reissue
15Cited by
11References
3Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jul 19, 2004 |
| Grant date | Sep 25, 2007 |
| Priority date | — |
| Expiry date | Jul 19, 2024 |
Classification
- Technology area (CPC —)General
Abstract
A method of female contraception involves administering a combination of estrogen and progestin for 60-110 consecutive days in which the daily amounts of estrogen and progestin are equivalent to about 5-35 mcg of ethinyl estradiol and about 0.025 to 10 mg of norethindrone acetate, respectively. The advantages include less menstrual bleeding, less patient anemia, less total exposure to medication, higher compliance rates and more lifestyle convenience for patients.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.